<unk>  binds uniquely to an epitope on the CD38 receptor and is the only CD38 antibody which can start apoptosis directly.<unk>  binds to a different CD38 epitope amino-acid sequence than does the anti-CD38 monoclonal antibody daratumumab. The binding with the CD38 receptor is mainly via the gamma heavy chains and are more potent than other CD38 antibodies such as daratumumab which can inhibit the enzymatic activity of CD38. Moreover,<unk>  inhibits the hydrolase activity of CD38. The antibodies show signs of improving antitumor immunity by eliminating regulatory T cells, B cells and myeloid-derived suppressor cells. The difference in binding between<unk>  and daratumumab is in the recognition of the different amino acid groups.<unk>  identifies 23 amino acids of CD38 to the contrary with daratumumab who has 27. The residue of Glu233 has a flexible sidechain and faces the N-terminal of Asp1 residue in the<unk>  light chain. The latter light chain of<unk>  is also flexible which makes the interaction between CD38/Glu233 and the Asp1 weaker than the other interactions between CD38 and<unk> . The caspase-dependent apoptotic pathway and the lysosomal mediated cell death pathway in MM cells is induced by<unk> . The MM cell death follows the downstream reactions of the lysosomal activation. The latter also activates the production of reactive oxygen species.
Isatuximab
Siltuximab
Margetuximab
Dinutuximab
Loncastuximab tesirine
Alirocumab
Daratumumab
Blinatumomab